Accidental, recreational heroin (and other opiate) overdose.
Conditions
Interventions
Product Name: Naloxone hydrochloride
Pharmaceutical Form: Injection*
INN or Proposed INN: Naloxone hydrochloride
CAS Number: 465-65-6
Cu
Sponsors
Brighton and Sussex Universities Hospitals Trust Research and Development Directorate
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: • Known or suspected opiate OD AND • Age >18 AND • Weight >40 kg (estimated) AND • Respiratory rate =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Exclusion criteria: • Tracheal intubation already performed OR • Improving neurological status OR • Active seizure OR • Documented hypoglycaemia OR • Other obvious cause for decreased level of consciousness OR • Known allergy to naloxone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Too see if titrated dose naloxone improves the likelihood of the opiate overdosed patient of reaching the definitive care setting i.e. the emergency department; Secondary Objective: To see if titrated dose naloxone improves the likelihood of successful enrolment in the local substance misuse service and whether there is a longer term reduction in 999 calls for opiate overdose To compare the relative rates of opiate-related side effects (airway compromise, aspiration, respiratory failure, hypotension) in the pre- and post-implementation group To look at the impact that titrated dose naloxone has on the local ambulance service ;Primary end point(s): Primary end point is follow up at the substance misuse service, the time frame for which depends on the date given for the appointment and starts from the date and time that the participant is enrolled | — |
Countries
United Kingdom
Outcome results
None listed